Related Experiment Videos
Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients
Insights
Ceftazidime effectively treated bacterial infections in children outside the central nervous system. This beta-lactam antibiotic demonstrated good clinical response with minimal adverse effects in pediatric patients.
Area of Science:
- Infectious Diseases
- Pediatric Pharmacology
- Antimicrobial Therapy
Background:
- Bacterial infections remain a significant cause of morbidity in children.
- The need for effective and safe antimicrobial agents in pediatric populations is critical.
- Ceftazidime, a third-generation cephalosporin, offers broad-spectrum activity against Gram-negative bacteria.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftazidime as monotherapy for childhood bacterial infections outside the central nervous system.
- To determine the appropriate dosing regimen for ceftazidime in pediatric patients.
- To assess the clinical and microbiological outcomes of ceftazidime treatment.
Main Methods:
- A prospective study involving 60 children aged 0.1 to 21 years with suspected bacterial infections.
- Administration of ceftazidime at 30 mg/kg per dose, up to 1 g every 8 hours.
- Isolation and identification of pathogens prior to treatment initiation.
- Clinical and microbiological assessments throughout the treatment period.
Main Results:
- All 60 children achieved a clinical response to ceftazidime therapy.
- Pathogens were isolated from 43 children before treatment.
- One child experienced a bacteriologic failure, and five were considered colonized post-therapy.
- Adverse reactions were primarily clinically insignificant laboratory parameter alterations.
Conclusions:
- Ceftazidime is an effective monotherapy for treating bacterial infections in children outside the CNS.
- An 8-hour dosing regimen of ceftazidime is well-tolerated and efficacious in pediatric patients.
- Ceftazidime represents a valuable therapeutic option for pediatric bacterial infections.
Abstract:
Ceftazidime, a new beta-lactam antibiotic, was used to treat 60 children with suspected bacterial infections occurring outside the central nervous system. The patients ranged in age from 0.1 to 21 years and received 30 mg of ceftazidime per kg up to a total single dose of 1 g administered every 8 h. Fifty-three pathogens were isolated from 43 children before the initiation of therapy. All children responded clinically, although one child failed bacteriologically and five children were considered colonized at the end of ceftazidime therapy. Adverse reactions associated with ceftazidime administration were primarily alterations in laboratory parameters and were clinically insignificant. Ceftazidime administered on an 8-h dosing regimen is effective monotherapy for the treatment of childhood infections.